
Biointron is pleased to announce that we will be attending the Antibody Therapeutics Conference (ATC) Taiwan 2026, taking place May 26 – 27, 2026, at the National Biotechnology Research Park in Taipei, Taiwan. This annual event brings together researchers, biopharma professionals, and industry innovators to explore the expanding landscape of antibody-based therapeutics and their applications.
Organized by the Taiwan Antibody Association, ATC Taiwan serves as a focused platform for scientific exchange and industry collaboration. The conference highlights advances in next-generation antibody formats, cancer immunotherapy, and applications in immune and infectious diseases, alongside discussions on translational development and biomanufacturing strategies. Through a combination of scientific sessions and networking opportunities, ATC continues to support the growth of Taiwan’s and the broader Asia-Pacific antibody ecosystem.
As a company dedicated to antibody discovery and engineering, Biointron looks forward to connecting with leading scientists and partners, sharing insights, and exploring opportunities that advance the development of innovative biologics. Participation in ATC Taiwan reflects our ongoing commitment to supporting efficient, high-quality antibody development across global markets.
We look forward to engaging with colleagues in Taipei and contributing to conversations that help shape the future of antibody therapeutics at ATC Taiwan 2026.
For more details about the event, please visit the ATC Taiwan 2026 website [https://antibody.org.tw/atc2026/]
Time: May 26 - 27, 2026
Location: International Conference Hall C201, National Biotechnology Research Park | Taipei, Taiwan
Biointron is excited to share that we will be attending BIO KOREA 2026, taking p……
Biointron is proud to announce our attendance at the AACR Annual Meeting 2026, t……
Biointron is excited to announce our participation in Immunology 2026, the 109th……
お客様の利便性を向上させるためにクッキーを使用しています。詳しくは プライバシーポリシー をご覧ください。


